Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies



Rating:

Share or cite this content

Citations should be made in the following way:
R. M. Huber (Munich, Germany). Second- and third-line therapies: what are the best options?. Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies

Member's Comments

No comment yet.

Related content which might interest you: Second-line injectables: are they essential to treat MDR/XDR-TB cases? Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy Year: 2017 First-line therapy Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009 Do we have any alternative therapeutic option beyond antibiotics? Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions Year: 2021 More hope for cure by individualised adjuvant treatment? Source: Annual Congress 2010 - Customised chemotherapy for lung cancer Year: 2010 Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim? Source: Breathe, 17 (3) 210056; 10.1183/20734735.0056-2021 Year: 2021 Four-month regimens: are they feasible? Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015 Which therapeutic options when CPAP fails?  Source: ERS Course 2017 - Paediatric noninvasive ventilation Year: 2017 Combating acquired resistance: are rebiopsies needed for guiding multi-line therapies? Source: International Congress 2015 – Non-small cell lung cancer (NSCLC): sequence, timing, and modality of multi-line therapies Year: 2015 Combination therapy in the era of immunotherapy Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007